D. Kanamori

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori, M. Moroni, N. Ibrahim, 2021, Breast Cancer Research and Treatment.

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

J. Chakrabarti, Z. Wainberg, J. Hoffman, 2019, Anti-cancer drugs.

A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.

G. Warshamana-Greene, P. Melone, J. McCarty, 2006, Experimental hematology.

Development of a novel loop-mediated isothermal amplification assay for ß-lactamase gene identification using clinical isolates of Gram-negative bacteria

D. W. Kim, S. Hayakawa, Donghyun Lee, 2023, Frontiers in Cellular and Infection Microbiology.

Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).

S. Dakhil, D. Slamon, J. Goldman, 2022, Journal of Clinical Oncology.